surmount-1 tirzepatide non-diabetic obesity weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers Tirzepatide as Compared with Semaglutide

And so I might just like titrate somebody up on the tiniest amount of thyroid where most doctors would be like, well, thats not enough to do anything

At 20 mg/mL , which is a more concentrated formulation often used to reduce injection volume, 2.5 mg equals 12.5 units (0.125 mL)

Today, physician-prescribed GLP-1 receptor agonists are being used for more long-term weight management

These are positive signs that your GLP-1 is doing its job, but its important to track how you feel so you can adjust meals and snacks thoughtfully

Wegovy is the same medication as Ozempic with the same active ingredient (semaglutide), but its specifically designed and licenced to treat weight loss, so it comes in different doses